Alicia Weakley is an accomplished pharmaceutical and biotechnology executive whose career has been defined by a passion for transforming complex clinical development strategies into operational excellence. With more than 25 years of experience spanning pharmaceutical companies, biotechnology organizations, and global contract research organizations (CROs), Alicia has built a distinguished reputation for helping organizations successfully navigate every stage of the clinical development lifecycle. Her expertise extends from early-phase planning through regulatory submission, global execution, vendor management, and process optimization, making her a trusted advisor to executive leadership teams seeking to accelerate drug development while protecting quality, adhering to country/local regulations and ICH GCP guidelines, and achieving timelines.
Throughout her career, Alicia has consistently demonstrated the ability to bridge scientific vision with disciplined business execution. She understands that a successful clinical development plan requires more than scientific innovation—it demands strategic planning, financial accountability, collaborative leadership, and operational precision. Her leadership philosophy focuses on creating scalable operating models that improve execution, mitigate risk, strengthen governance, and ultimately increase patient access to groundbreaking therapies. This balanced approach has allowed her to deliver measurable results while building trusted relationships with sponsors, executive teams, regulators, clinical investigators, and global partners.
Today, Alicia serves as the Founder and Independent Clinical Strategy & Operations Consultant for Weakley Life Sciences Consulting L.L.C., where she advises pharmaceutical and biotechnology organizations on the successful execution of complex clinical development programs. Her consulting practice focuses on helping sponsors translate ambitious clinical strategies into executable operational plans that protect study endpoints while maintaining financial discipline and regulatory compliance. She provides executive advisory services in protocol feasibility, regulatory readiness, fractional clinical operations leadership, CRO and functional service provider selection, request for proposal development, contract negotiation, vendor oversight, clinical trial recovery, and portfolio oversight. Her work is particularly concentrated within autoimmune diseases, rare diseases, orphan drug development, biologics, infectious diseases, and cell and gene therapy programs.
Before launching her consulting practice, Alicia spent more than nine years with IQVIA Biotech, a dedicated division servicing biopharma, where she progressed through several senior leadership positions that reflected both her operational expertise and strategic capabilities. As Director of Clinical Project Management, she advised biotechnology sponsors on the execution of complex global clinical trials while partnering closely with executive, monitoring, medical, regulatory, data management and cross-functional leaders to improve protocol feasibility, country selection, resource planning, and adaptive clinical delivery models. Earlier, as Director of Business Performance, she led initiatives that enhanced operational governance, financial forecasting, portfolio visibility, and executive reporting. Her leadership contributed to more than $20 million in revenue acceleration while improving utilization metrics, financial transparency, and organizational performance across multiple therapeutic portfolios within IQVIA Biotech. Throughout her tenure, she became widely recognized for her ability to recover challenged programs, create innovative solutions to mitigate risks, and develop governance frameworks that consistently improved execution, endpoint quality and established strong partnerships.
Alicia’s foundation in global clinical leadership was established during more than fourteen years with Eli Lilly and Company, where she held several progressively responsible leadership positions. As Global Clinical Trial Project Manager supporting autoimmune programs, she directed Phase II through Phase IV international clinical studies from protocol development through regulatory submission, inspection readiness, and commercial launch. She played an instrumental role supporting pivotal Phase III clinical trials for ixekizumab (Taltz), overseeing global execution and managing clinical trial budgets exceeding $100 million. Her responsibilities included collaboration with clinical scientists and Medical Director on protocol writing, lead for submission and regulatory approval, biostatistic deliverables, and CRO vendor management while supporting Pre-IND planning, NDA/BLA submissions, health technology assessments, and market access initiatives. These experiences strengthened her ability to integrate scientific development with strategic business objectives while maintaining exceptional operational discipline.
Earlier in her career, Alicia developed a uniquely diverse background that combines clinical research with enterprise technology leadership. As a Clinical Research Associate, she supported Phase II through Phase IV endocrine clinical trials, site qualification, investigator training, and patient enrollment initiatives. Prior to transitioning into clinical operations, she served in Information Technology Project Management for Global Sales & Marketing, supporting enterprise-wide SAP implementation initiatives for Eli Lilly’s global organization. This uncommon combination of technical systems expertise, project management, business operations, and clinical execution provides Alicia with a comprehensive perspective that enables her to identify opportunities for innovation, efficiency, and organizational transformation.
Across every stage of her career, Alicia has become highly respected for her expertise in CRO management, vendor qualification, RFP development, contract negotiation, financial forecasting, revenue optimization, regulatory inspection readiness, clinical trial budgeting, governance development, risk mitigation, and global program oversight. She has successfully led multidisciplinary teams across North America, Europe, Africa, the Middle East, Asia, and other international regions, giving her valuable insight into multinational operations, cultural collaboration, and geographically diverse regulatory environments. Whether advising emerging biotechnology companies or supporting established global pharmaceutical organizations, Alicia consistently delivers practical solutions that strengthen execution while improving long-term business performance.
Alicia earned her Master of Business Administration with Honors from the Crummer Graduate School of Business at Rollins College after receiving her Bachelor of Science in Business Information Technology with Honors from Indiana University Bloomington Kelley School of Business. Her educational background complements her extensive professional experience by providing a strong foundation in strategic leadership, financial management, technology integration, and organizational effectiveness. She remains committed to continuous improvement and lifelong learning, consistently applying both business and clinical expertise to solve increasingly complex challenges facing the life sciences industry.
Beyond her executive accomplishments, Alicia is driven by a genuine desire to improve healthcare outcomes through better organizational leadership. She actively participates in civic organizations, learning to be an angel investor for start-ups and seeks opportunities to contribute at the board level because she believes experienced governance can accelerate innovation, strengthen organizational performance, and ultimately improve patient access to life-changing therapies. She views board service as an opportunity to leverage decades of executive leadership, strategic thinking, operational excellence, and collaborative problem-solving to help organizations achieve sustainable growth while fulfilling their missions.
Colleagues recognize Alicia as a thoughtful strategist, trusted advisor, and decisive leader who remains focused on both organizational success and patient impact. Her ability to combine executive-level business leadership with deep clinical operations expertise allows her to navigate complex environments with confidence and integrity. Whether leading global development programs, optimizing operational performance, negotiating strategic partnerships, or advising executive leadership teams, Alicia consistently demonstrates the professionalism, vision, and disciplined execution that define exceptional leadership in today’s life sciences industry.
Character:
Alicia leads with integrity, accountability, and a deep commitment to improving patient outcomes through operational excellence. She builds lasting relationships by fostering trust, collaboration, and a culture of continuous improvement.
Knowledge:
She brings more than twenty-five years of expertise in pharmaceutical development, biotechnology, global clinical operations, and executive leadership. Her comprehensive understanding of clinical strategy, regulatory requirements, financial management, and operational execution enables organizations to make confident, informed decisions.
Strategic:
Alicia excels at transforming complex clinical development objectives into scalable operational frameworks that improve governance, execution, and business performance. She consistently anticipates risks, identifies opportunities for optimization, and develops practical strategies that deliver measurable results.
Communication:
Communicating with clarity, confidence, and professionalism across executive leadership teams, global stakeholders, clinical partners, and regulatory organizations. She has a proven ability to simplify complex challenges, build consensus, and align diverse teams around common organizational goals.
